Clinical Trial Update: F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer [Phase 2, Phase 3]

View source ↗

Summary

The Phase 2/3 clinical trial evaluating F-choline PET for early response assessment in castration-resistant prostate cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Snippet

Sponsor: University Hospital, Grenoble | Conditions: Castration-resistant Prostate Cancer | Phase 2, Phase 3 | Status: TERMINATED